<div id="readability-page-1"><p>Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) insider Matthew Henn sold 1,257 shares of Seres Therapeutics stock in a transaction on Saturday, November 15th. The stock was sold at an average price of $17.30, for a total transaction of $21,746.10. Following the completion of the transaction, the insider directly owned 7,527 shares of the company's stock, valued at $130,217.10. The trade was a 14.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink.</p><div><p><span></span><span>Get <strong>Seres Therapeutics</strong> alerts:</span></p></div><h2>Seres Therapeutics Price Performance</h2><p>Shares of NASDAQ MCRB traded up $3.07 during mid-day trading on Tuesday, hitting $24.71. 890,977 shares of the company's stock traded hands, compared to its average volume of 121,438. Seres Therapeutics, Inc. has a 1 year low of $6.53 and a 1 year high of $25.85. The company's 50-day moving average is $17.74 and its two-hundred day moving average is $13.97. The company has a market capitalization of $223.55 million, a P/E ratio of -5.48 and a beta of 0.19. </p><h2>Analysts Set New Price Targets</h2><p>MCRB has been the subject of a number of recent research reports. Weiss Ratings  reiterated a &#34;sell (d)&#34; rating on shares of Seres Therapeutics in a report on Monday. Canaccord Genuity Group raised their price target on Seres Therapeutics from $14.00 to $22.00 and gave the stock a &#34;buy&#34; rating in a research report on Wednesday, September 24th. One investment analyst  has rated the stock with a Buy rating, one  has assigned  a Hold rating and two have issued  a Sell rating to the company. Based on data from MarketBeat.com, the stock  has an average rating of &#34;Reduce&#34; and an average target price of $14.33.</p><p><b>Check Out Our Latest Analysis on Seres Therapeutics</b></p><h2>Hedge Funds Weigh In On Seres Therapeutics</h2><p>Hedge funds have recently bought and sold shares of the business. Goldman Sachs Group Inc. lifted its position in shares of  Seres Therapeutics by 40.9% during the first quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company's stock worth $52,000 after purchasing an additional 21,679 shares during the last quarter.  Invesco Ltd. increased its stake in  Seres Therapeutics by 193.2% in the 1st quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company's stock worth $96,000 after buying an additional 89,995 shares during the period.  Bank of America Corp DE lifted its holdings in  Seres Therapeutics by 2,772.6% during the 3rd quarter. Bank of America Corp DE now owns 5,343 shares of the biotechnology company's stock valued at $103,000 after buying an additional 5,157 shares in the last quarter.  XTX Topco Ltd bought a new stake in  Seres Therapeutics during the 2nd quarter valued at about $249,000.  Finally, Schonfeld Strategic Advisors LLC purchased a new stake in  Seres Therapeutics in the 3rd quarter valued at about $557,000. Institutional investors own  59.34% of the company's stock. </p><h2>About Seres Therapeutics</h2> (Get Free Report)<p>Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Seres Therapeutics</li><li>Health Care Stocks Explained: Why You Might Want to Invest</li><li>What’s on the Thanksgiving Table? A Stock Pick for Every Course</li><li>Growth Stocks: What They Are, Examples and How to Invest</li><li>Why Home Depot’s Pain Could Be a Long-Term Investor’s Gain</li><li>Insider Buying Explained: What Investors Need to Know</li><li>Qualcomm’s Bulls Are Running Out of Room to Be Wrong</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUNSQg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUNSQg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Seres Therapeutics Right Now?</h2><p>Before you consider Seres Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Seres Therapeutics wasn't on the list.</p><p>While Seres Therapeutics currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

MCRB

<p>Matthew Henn, an insider at Seres Therapeutics, sold 1,257 shares at $17.30 each, totaling $21,746.10. This sale reduced his ownership by 14.31%, leaving him with 7,527 shares valued at $130,217.10. The transaction was disclosed in an SEC filing. Seres Therapeutics' stock price rose to $24.71, with a market cap of $223.55 million. Analysts have mixed ratings on the stock, with a recent price target increase from Canaccord Genuity Group to $22.00. Institutional investors own 59.34% of the company.</p>

Insider Selling: Seres Therapeutics (NASDAQ:MCRB) Insider Sells 1,257 Shares of Stock